LXRβ-Selective Tricyclic Agonist Developed with New [4σ+4π] and [4σ+4π–1] Cycloaddition Strategy

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2024; 20(07): 0760
DOI: 10.1055/s-0043-1763969

Innovative Drug Discovery and Development

Contributor(s):

Dirk Trauner

,

Joseph A. Flores

type-I cycloaddition - [4σ+4π] cycloaddition - benzocyclobutenone - LXR agonist

Article published online:
14 June 2024

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany